Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Chcesz wydać pracę habilitacyjną, doktorską czy monografię? Zrób to w Wydawnictwie Borgis – jednym z najbardziej uznanych w Polsce wydawców książek i czasopism medycznych. W ramach współpracy otrzymasz pełne wsparcie w przygotowaniu książki – przede wszystkim korektę, skład, projekt graficzny okładki oraz profesjonalny druk. Wydawnictwo zapewnia szybkie terminy publikacji oraz doskonałą atmosferę współpracy z wysoko wykwalifikowanymi redaktorami, korektorami i specjalistami od składu. Oferuje także tłumaczenia artykułów naukowych, skanowanie materiałów potrzebnych do wydania książki oraz kompletowanie dorobku naukowego.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - New Medicine 2/2010, s. 66-70
*László Medve1, Emil Préda1, Tibor Gondos2
Acute renal replacement therapy in the intensive care unit: theoretical foundations and terms
1Dr. Kenessey Albert Hospital, Department of Anaesthesiology and Intensive Care Medicine, Balassagyarmat
Head: Dr. Szabó Géza, General Director
2Semmelweis University, Faculty of Health Science, Department of Oxyology and Emergency Care, Budapest
Head: Prof. Dr. Mészáros Judit, Dean of Faculty
The incidence of acute renal failure (ARF) in intensive care units (ICUs) has been continuously on the rise over the years. In the current education system nurses do not receive adequate training to carry out RRT in the ICUs; therefore, in the following, we will provide an overview of the theoretical basics of ARF and will summarize the problems of current treatment modalities. The AKIN Working Group created the concept of acute kidney injury (AKI), replacing the nomenclature of ARF, and set the stages. Recent prospective studies have demonstrated that an early start of RRT is beneficial and increases the patient survival rate. Many factors can affect the completion of treatment and the modality of treatment. RRT needs a well equipped intensive care unit with a well trained staff. During the training process, it is worth for at least one or two specialists to spend a few weeks at a chronic dialysis station, and in an intensive care unit, where haemodialysis is routinely administered. After becoming familiar with the theoretical basis of RRT and after fulfilling the requirements for optimal treatment conditions, our department may begin the introduction and selection of optimal treatment modalities for renal replacement procedures. During the practical application of the chosen treatment method, we may still encounter problems.
The incidence of acute renal failure (ARF) in intensive care units (ICUs) has been continuously on the rise over the years (1, 2, 3, 4). This appears to be primarily related to the increasing number of patients with severe sepsis and multiple organ failure. There are no widely accepted guidelines when to begin the renal replacement therapy (RRT) in these cases; however, there is a consensus to start RRT immediately after early signs of ARF are recognized. There is a reasonable request for the ICUs to carry out RRT, because the technical background, with the new, mobile, easy to use equipment is readily available. In the current education system nurses do not receive adequate training to carry out RRT in the ICUs; therefore, in the following, we will provide an overview on the theoretical basics of ARF and will summarize the problems of current treatment modalities.
ARF epidemiology
The most recent literature data suggest that 1-25% of patients admitted to ICUs have ARF and 72.4% of these patients need renal support therapy (5). Unfortunately, despite the rapidly improving intensive care, the mortality of patients admitted with ARF is still high (15-60%).
ARF definition
In recent years, expert groups have developed a uniform definition of ARF, and grading systems to evaluate its severity (RIFLE and AKIN criteria). These are adopted and used by many intensive care societies worldwide. Both RIFLE and AKIN criteria define ARF as renal impairment when there is a sudden kidney failure (within 48 hours) when the absolute increase of the serum creatinine level exceeds or is equal to 0.3 mg/dl (26.4 mmol/l), which is expressed as an increase of 50% of the baseline value; and the decrease of urine output by 0.5 ml/kg body weight/hour below the baseline value over a period of 6 hours. The criteria above include the level of serum creatinine, absolute and percentage changes, thus eliminating the age, gender, body mass index-related individual differences and the need for basic knowledge of creatinine value. However, this system assumes that at least two serum creatinine measurements are made within 48 hours (7).
Criteria for the classification of the degree of severity of ARF
The Acute Dialysis Quality Initiative (ADQI) at the 2002 Consensus Conference of Vicenza issued the RIFLE criteria to define ARF (5, 6). Evaluating diagnostic and prognostic usefulness of criteria is ongoing; it appears that the nomenclature and definitions are, in general, good, but they need refining. Efforts of refining the criteria resulted in an AKI-network consensus, which modified the RIFLE criteria. Therefore, from 2007 we are no longer talking about ARF, but acute renal impairment. Currently, several multicentre studies have demonstrated that the RIFLE (R = risk, I = injury, F = failure, L = loss, E = end-stage renal disease) classification is valid for assessment of the severity of ARF (tab. 1). The AKIN Working Group created the concept of acute kidney injury (AKI), replacing the nomenclature of ARF, and set the stages (tab. 2). From the point of view of routine practice, the RIFLE and AKIN criteria are almost the same; there are only three subtle differences.
Table 1. Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification.
ClassGlomerular filtration rate criteriaUrine output criteria
RiskSerum creatinine × 1.5< 0.5 ml/kg/hour × 6 hours
InjurySerum creatinine × 2< 0.5 ml/kg/hour × 12 hours
FailureSerum creatinine × 3, or serum creatinine ≥ 4 mg/dl with an acute rise > 0.5 mg/dl< 0.3 ml/kg/hour × 24 hours, or anuria × 12 hours
LossPersistent acute renal failure = complete loss of kidney function > 4 weeks
End-stage kidney diseaseEnd-stage kidney disease > 3 months
Table 2. Classification/staging system for acute kidney injurya.
StageSerum creatinine criteriaUrine output criteria
1aIncrease in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 ?mol/l) or increase to more than or equal to 150% to 200% (1.5- to 2-fold) from baselineLess than 0.5 ml/kg per hour for more than 6 hours
2bIncrease in serum creatinine to more than 200% to 300% (> 2- to 3-fold) from baselineLess than 0.5 ml/kg per hour for more than 12 hours
3cIncrease in serum creatinine to more than 300% (> 3-fold) from baseline (or serum creatinine of more than or equal to 4.0 mg/dl (≥ 354 ?mol/l) with an acute increase of at least 0.5 mg/dl (44 ?mol/l))Less than 0.3 ml/kg per hour for 24 hours or anuria for 12 hours
aModified from RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria. The staging system proposed is a highly sensitive interim staging system and is based on recent data indicating that a small change in serum creatinine influences outcome. Only one criterion (creatinine or urine output) has to be fulfilled to qualify for a stage.
b200% to 300% increase = 2- to 3-fold increase.
cGiven wide variation in indications and timing of initiation of renal replacement therapy (RRT), individuals who receive RRT are considered to have met the criteria for stage 3 irrespective of the stage they are in at the time of RRT.
1. According to the AKIN, a slight increase in serum creatinine values is enough to define ARF.
2. AKIN introduced the time factor because the ARF diagnosis needs an elevated serum creatinine for at least 48 hours.
3. They eliminated the „loss and ESRD” category, because it represents the outcome of kidney disease and not the diagnosis.
Renal replacement indications for treatment of ARF
ARF may require RRT if the patient's glomerular filtration rate (GFR) decreases acutely and the level of toxic material increases significantly and/or there is a fluid overload. In practice, however, conventional indications for the treatment of ARF, the aetiology of which may be renal or non-renal, are accepted (tab. 3). When considering the indications, the rule of thumb is that the existence of one condition provides grounds for consideration of RRT, the presence of two conditions is a clear indication, and the presence of more indications means that RRT has to be initiated even before reaching pathological creatinine levels. The non-renal indication of continuous RRT is not yet sufficiently well established.
Table 3. Renal and non-renal indications of renal replacement therapy.
Non obstructív oliguria (urine < 200 mL/12 h) or anuriaDialysing agent poisoning
Progressive azotemia, even without clinical signs (blood urea > 30 mmol/l or blood urea nitrogen > 100 mg Hiperthermia (core temperature > 39,5°C)
Metabolic acidosis, drug therapy refractoryThe need of large quantities of blood in coagulation, in which there is pulmonary edema/ARDS risk
The existence of uremic organ symptoms: encephalopathy, myopathy, pericarditis, uremic bleeding diathesises
Hyperkalemia, drug therapy, refractory (plasma K +> 6.5 mmol/l or rapidly rising)
Progressive severe hyper/hyponatremia (Na +> 160 or <115 mmol/l)
Clinically significant organ edema, especially pulmonary edema
Intravascular fluid administration which is drug therapy refractory
The timing of initiation of treatment

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

1. Pisoni R, Wille KM, Tolwani AJ: The epidemiology of severe acute kidney injury: from BEST to PICARD, in acute kidney injury: new concepts. Nephron Clin Pract 2008; 109(4): 188-91. 2. Mehta RL et al.: Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney International 2004; 66: 1613-1621. 3. Uchino S et al.: Continuous renal replacement therapy: A worldwide practice survey. The Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Med 2007; 33: 1563-1570. 4. Bagshaw SM, George C, Bellomo R: Early acute kidney injury and sepsis: a multicentre evaluation, Critical Care 2008; 12: R47. 5. Mehta RL et al.: for the Acute Kidney Injury Network, Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury, Critical Care 2007; 11: R31. 6. Hoste EAJ et al.: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Critical Care, 2006; 10: R73. 7. Kellum JA, Bellomo R, Ronco C: Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109(4): c182-7. 8. Paul M Palevsky: Renal replacement therapy I: indications and timing. Critical Care Clinics 2005; 21(2): 347-356. 9. Gibney RT et al.: When should renal replacement therapy for acute kidney injury be initiated and discontinued? Blood Purif 2008; 26(5): 473-84. 10. The VA/NIH Acute Renal Failure Trial Network: Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury 2008; 359: 7-20. 11. Finfer S et al.: RENAL Study Investigators. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Crit Care Resusc 2009 11(1): 58-66. 12. Ronco C, Bellomo R: Basic mechanisms and definitions for continuous renal replacement therapies. Int J Artificial Organs 1996; 19: 95-99. 13. Medve L, Preda E, Gondos T: The practice of renal replacement therapy in the intensive care unit. 14. Brunet S et al.: Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486-492. 15. Pannun et al.: Renal Replacement Therapy in Patients With Acute Renal Failure. JAMA 2008; 299(7): 793-808. 16. Michael Joannidis1 and Heleen M Oudemans-van Straaten: Clinical review: Patency of the circuit in continuous renal replacement therapy, Critical Care 2007; 11: 218 (doi:10.1186/cc5937). 17. Locatelli F, Di Filippo S, Manzoni C: Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant 2000; 15 (Suppl. 2): 37-44. 18. Mehta RL et al.: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31. 19. Paganini EP: Continuous replacement modalities in acute renal dysfunction. In: Paganini EP, ed. Acute continuous renal replacement therapy. Boston: Martinus Nijhoff 1986: 7-42. 20. Bellomo R, Ronco C, Mehta R: Nomenclature for continuous renal replacement therapies. Am J Kidney Dis 1996; 28: S2-S7.
otrzymano: 2010-04-21
zaakceptowano do druku: 2010-05-05

Adres do korespondencji:
*László Medve
Cím: 3100. Salgótarján, Kemping út 2
phone: 36 30 6966 438

New Medicine 2/2010
Strona internetowa czasopisma New Medicine